-

Eurofins Environment Testing Launches PFAS Exposure Self-Collection Blood Test

LUXEMBOURG--(BUSINESS WIRE)--Per- and Polyfluorinated Alkyl Substances (PFAS), such as PFOA and PFOS, known as “forever chemicals”, characteristically resist natural breakdown in the environment and human bodies. The US Centers for Disease Control and Prevention (CDC) reports that exposure to these chemicals may cause adverse health effects.

In a leap forward for PFAS identification through blood testing, Eurofins (Paris:ERF) Environment Testing and its research partners have developed a self-administered sampling kit, PFAS Exposure™. The kit is the first of its kind and uses a simple finger prick. To date, testing for PFAS in blood has relied on serum as an estimation for whole blood and required a blood draw conducted by a healthcare practitioner.

Knowledge of PFAS levels in blood can assist in understanding PFAS exposure from one’s occupation, food, drinking water, indoor air, and consumer products such as cookware and clothing and the environmental effects this has on humans.

Eurofins’ PFAS Exposure™ collection kits are an all-in-one solution that include the essentials for collection and transport, allowing participants to self-collect samples at home or work, and submit them directly to the laboratory.

The PFAS Exposure kit is available through Eurofins’ at-home health testing business, empowerDX. Kits can be purchased online for $399 and are shipped directly to the customers home or business.

Increasing knowledge of PFAS in blood

Eurofins will provide data for 47 PFAS compounds in whole blood, expanding on the CDC National Health and Nutrition Examination Survey (NHANES) study and database where 16 PFAS compounds in serum are reported.

Further information: www.EurofinsPFAS.com

About Eurofins Environment Testing America

The Eurofins Environment Testing network in the US contributes to a clean and safe environment by providing market-leading laboratory testing, monitoring, and consulting services to a wide range of industrial companies, environmental consultants, contractors, retailers and government authorities.

About empowerDX

empowerDX is the online shop for easy at-home health testing. empowerDX specializes in FDA-authorized COVID-19 testing, women’s health, men’s health, sexual health and general wellness testing. empowerDX is positioned to lead the market for cutting edge, self-collected diagnostic and non-diagnostic testing.

To learn more: empowerdxlab.com

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. With 55,000 staff across a network of 900 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

Contacts

Brian Williams
ir@eurofins.com

Eurofins

BOURSE:ERF

Release Versions

Contacts

Brian Williams
ir@eurofins.com

More News From Eurofins

Eurofins MET Laboratories Opens New Safety, EMC, Wireless, and Renewable Energy Laboratory in the Boston Tech Corridor

BOSTON--(BUSINESS WIRE)--Eurofins MET Laboratories, part of the Eurofins Electrical & Electronics global network, announces the opening of its new state-of-the-art 60,000-square-foot testing laboratory in Littleton, Massachusetts – a prime location in the Boston innovation corridor. Positioned at the epicenter of New England's med-tech, wireless innovation, clean energy, and advanced electronics ecosystem, the capabilities of this laboratory further position Eurofins MET Laboratories as the...

Eurofins Scientific SE: Weekly Report on Share Repurchases from 26th January to 30th January 2026

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 26/01/2026 FR0014000MR3 5 000 70.7336 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 27/01/2026 FR0014000MR3 5 000 70.9680 XPAR EUROFINS SCIENTIFIC 529900JEHFM47...

Eurofins Delivers FY 2025 Objectives with a 24% EPS Growth, Accelerating Organic Revenue Growth, Margin Expansion, and Higher Free Cash Flow and Confirms Its 2027 Objectives

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF) pre-publishes below its preliminary unaudited consolidated financial results for the year ending 31 December 2025, as described in the first paragraphA of the Business Review section of this press release. Financial highlights in FY 2025 Basic EPS8 grew 24% to €2.31 in 2025 vs €1.87 in 2024, driven by a strong operating performance and starting to reap the benefits from Eurofins five-year investment programme in its hub and spok...
Back to Newsroom